Anzeige
Mehr »
Login
Mittwoch, 28.02.2024 Börsentäglich über 12.000 News von 684 internationalen Medien
Feuerwerk fürs Depot: Rohstoff-Geheimtipp! Startet JETZT der Kursturbo?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DNZ4 | ISIN: US75915K3095 | Ticker-Symbol: 7RG0
Frankfurt
28.02.24
08:01 Uhr
1,370 Euro
+0,080
+6,20 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
REGULUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
REGULUS THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,3601,42009:49
1,3601,42009:47

Aktuelle News zur REGULUS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12.01.Regulus Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans1
02.01.Regulus Therapeutics Inc.: Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)123SAN DIEGO, Jan. 2, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs...
► Artikel lesen
27.12.23Regulus Therapeutics files for $150M mixed shelf1
10.11.23Regulus Therapeutics GAAP EPS of -$0.401
10.11.23Regulus Therapeutics Inc reports results for the quarter ended in September - Earnings Summary1
09.11.23Regulus Therapeutics Inc. - 10-Q, Quarterly Report1
09.11.23Regulus Therapeutics Inc. - 8-K, Current Report1
09.11.23Regulus Therapeutics Inc.: Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates84Announced positive topline data from the first cohort of patients in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease...
► Artikel lesen
20.09.23Regulus Therapeutics Releases Early Data From Of Investigational For Rare Type Of Kidney Disease2
20.09.23Regulus posts early Phase 1 data for lead asset in kidney disease1
20.09.23Regulus Reports Positive Topline Data From First Cohort Of Patients In Phase 1b Study Of RGLS84293
08.08.23Regulus Therapeutics Inc.: Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates226First patient dosed in second cohort of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 R&D Day to discuss our ADPKD...
► Artikel lesen
20.06.23Regulus Therapeutics Inc.: Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital233Program advances to lead compound evaluation in preclinical in vivo models Preliminary data for in vivo studies are expected in second half of 2023 SAN DIEGO, June 20, 2023 /PRNewswire/ -- Regulus...
► Artikel lesen
11.05.23Regulus Therapeutics Inc.: Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates540Enrollment completed in first cohort of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 Closed $15.0 million private...
► Artikel lesen
23.03.23Regulus Therapeutics Inc.: Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates332Enrollment progressing in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) Top-line data in the first cohort of RGLS8429-treated...
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1